Annual EBIT
-$114.77 M
-$10.42 M-9.98%
December 31, 2023
Summary
- As of February 7, 2025, STOK annual earnings before interest & taxes is -$114.77 million, with the most recent change of -$10.42 million (-9.98%) on December 31, 2023.
- During the last 3 years, STOK annual EBIT has fallen by -$61.73 million (-116.37%).
- STOK annual EBIT is now -1966.49% below its all-time high of -$5.55 million, reached on December 31, 2017.
Performance
STOK EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$30.00 M
-$661.00 K-2.25%
September 30, 2024
Summary
- As of February 7, 2025, STOK quarterly earnings before interest & taxes is -$30.00 million, with the most recent change of -$661.00 thousand (-2.25%) on September 30, 2024.
- Over the past year, STOK quarterly EBIT has dropped by -$2.77 million (-10.17%).
- STOK quarterly EBIT is now -1469.19% below its all-time high of -$1.91 million, reached on March 31, 2018.
Performance
STOK Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$117.30 M
-$2.77 M-2.42%
September 30, 2024
Summary
- As of February 7, 2025, STOK TTM earnings before interest & taxes is -$117.30 million, with the most recent change of -$2.77 million (-2.42%) on September 30, 2024.
- Over the past year, STOK TTM EBIT has dropped by -$4.94 million (-4.40%).
- STOK TTM EBIT is now -6035.09% below its all-time high of -$1.91 million, reached on March 31, 2018.
Performance
STOK TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
STOK EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -10.0% | -10.2% | -4.4% |
| 3 y3 years | -116.4% | -10.2% | -4.4% |
| 5 y5 years | -798.0% | -10.2% | -4.4% |
STOK EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -33.4% | at low | -22.3% | +9.8% | -36.3% | +1.0% |
| 5 y | 5-year | -221.7% | at low | -171.1% | +9.8% | -228.8% | +1.0% |
| alltime | all time | -1966.5% | at low | -1469.2% | +9.8% | -6035.1% | +1.0% |
Stoke Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$30.00 M(+2.3%) | -$117.30 M(+2.4%) |
| Jun 2024 | - | -$29.34 M(+3.4%) | -$114.53 M(-3.3%) |
| Mar 2024 | - | -$28.37 M(-4.1%) | -$118.45 M(+3.2%) |
| Dec 2023 | -$114.77 M(+10.0%) | -$29.59 M(+8.6%) | -$114.77 M(+2.1%) |
| Sep 2023 | - | -$27.23 M(-18.1%) | -$112.36 M(+0.1%) |
| Jun 2023 | - | -$33.26 M(+34.7%) | -$112.28 M(+7.7%) |
| Mar 2023 | - | -$24.69 M(-9.1%) | -$104.25 M(-0.1%) |
| Dec 2022 | -$104.36 M(+21.3%) | -$27.18 M(+0.1%) | -$104.36 M(+2.6%) |
| Sep 2022 | - | -$27.15 M(+7.6%) | -$101.71 M(+4.6%) |
| Jun 2022 | - | -$25.24 M(+1.8%) | -$97.24 M(+3.4%) |
| Mar 2022 | - | -$24.80 M(+1.1%) | -$94.03 M(+9.3%) |
| Dec 2021 | -$86.06 M | -$24.53 M(+8.1%) | -$86.06 M(+13.1%) |
| Sep 2021 | - | -$22.68 M(+3.0%) | -$76.13 M(+13.4%) |
| Jun 2021 | - | -$22.03 M(+30.9%) | -$67.15 M(+15.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$16.83 M(+15.4%) | -$58.14 M(+9.6%) |
| Dec 2020 | -$53.04 M(+48.7%) | -$14.59 M(+6.4%) | -$53.04 M(+7.1%) |
| Sep 2020 | - | -$13.71 M(+5.4%) | -$49.53 M(+8.5%) |
| Jun 2020 | - | -$13.01 M(+10.9%) | -$45.66 M(+11.1%) |
| Mar 2020 | - | -$11.73 M(+6.0%) | -$41.09 M(+15.2%) |
| Dec 2019 | -$35.68 M(+179.1%) | -$11.07 M(+12.5%) | -$35.68 M(+22.4%) |
| Sep 2019 | - | -$9.84 M(+16.5%) | -$29.15 M(+28.8%) |
| Jun 2019 | - | -$8.45 M(+33.6%) | -$22.63 M(+31.6%) |
| Mar 2019 | - | -$6.32 M(+39.2%) | -$17.19 M(+34.5%) |
| Dec 2018 | -$12.78 M(+130.1%) | -$4.54 M(+36.9%) | -$12.78 M(+55.1%) |
| Sep 2018 | - | -$3.32 M(+10.2%) | -$8.24 M(+67.4%) |
| Jun 2018 | - | -$3.01 M(+57.4%) | -$4.92 M(+157.4%) |
| Mar 2018 | - | -$1.91 M | -$1.91 M |
| Dec 2017 | -$5.55 M | - | - |
FAQ
- What is Stoke Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Stoke Therapeutics?
- What is Stoke Therapeutics annual EBIT year-on-year change?
- What is Stoke Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Stoke Therapeutics?
- What is Stoke Therapeutics quarterly EBIT year-on-year change?
- What is Stoke Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Stoke Therapeutics?
- What is Stoke Therapeutics TTM EBIT year-on-year change?
What is Stoke Therapeutics annual earnings before interest & taxes?
The current annual EBIT of STOK is -$114.77 M
What is the all time high annual EBIT for Stoke Therapeutics?
Stoke Therapeutics all-time high annual earnings before interest & taxes is -$5.55 M
What is Stoke Therapeutics annual EBIT year-on-year change?
Over the past year, STOK annual earnings before interest & taxes has changed by -$10.42 M (-9.98%)
What is Stoke Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of STOK is -$30.00 M
What is the all time high quarterly EBIT for Stoke Therapeutics?
Stoke Therapeutics all-time high quarterly earnings before interest & taxes is -$1.91 M
What is Stoke Therapeutics quarterly EBIT year-on-year change?
Over the past year, STOK quarterly earnings before interest & taxes has changed by -$2.77 M (-10.17%)
What is Stoke Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of STOK is -$117.30 M
What is the all time high TTM EBIT for Stoke Therapeutics?
Stoke Therapeutics all-time high TTM earnings before interest & taxes is -$1.91 M
What is Stoke Therapeutics TTM EBIT year-on-year change?
Over the past year, STOK TTM earnings before interest & taxes has changed by -$4.94 M (-4.40%)